Login
Welcome to our abstracts submission platform !
You are invited to submit a clinical abstract to present your experience and share your expertise. Click on the button below "Submit an abstract".
To access to your account and follow up the validation of your submission(s), log in by entering your email and password into the following fields.
If you are a member of the Approval Committee, access to your account by entering your email and password into the following fields.
Here are some submission guidelines :
- Abstracts can only be submitted via the online form, abstracts submitted by fax or email will not be accepted.
- Abstracts must be submitted in English.
- The presenting author of an accepted abstract must register and attend the congress.
- The number of submissions is limited to 3 per presenting author.
- The number of authors is limited to 20 per abstract.
- Provide a short specific title indicating the scientific content of the abstract.
Disclosure of potential conflict of interest (e.g., grant support, consultancy, membership on advisory councils, speaker’s bureau) by all authors and source of funding are mandatory. The submitting author is responsible for collecting a Conflict-of-interest form for all co-authors. All disclosures should be listed within the last 3 years.
To submit your clinical abstract, please decide which category, indicated in the list below, you will select for your work. The Approval Committee reserves the right to modify the category, if it appears not appropriate.
- Pathology
- Clinical
- Basic Science
- Translational science
- Education
- Health policy
- Psychosocial aspects
Abstracts submission deadline : June 10th, 2024
Abstracts submitted via commercial entities will be considered. However, these abstracts should report results from collaborative research conducted by independent (non-commercial) investigators. Investigators, as contributing authors who are employees of commercial entities will only be accepted if independent (academic, clinical and/or scientific) investigators are included as authors. The presenting author should not be an employee of the company.
Systematic review/meta-analysis abstracts are acceptable.
Trials in progress (TiP) can be accepted as posters/e-posters but will not be accepted as oral presentations. TiP abstracts have a separate category/topic.
Encore abstracts (from key data presented at 2022 international meeting as an oral presentation) can be accepted only if have not been published; with modification and new data, if possible. In case of a conflict of interest, please do not hesitate to contact us for clarification.
If several abstracts are based on similar analyses of the same database and one of them is selected for oral presentation, the authors might be asked to combine some/all data into one presentation.
Case reports for single cases will not be accepted unless they contain substantial translational work.
Late Breaking Abstracts (LBA) are generally reserved for newly emerging data from declared prospective studies that is not available at the time of abstract submission. These could be for initial presentation of results, or significant secondary endpoint analyses. A placeholder LBA must be submitted containing the preliminary title, background, methods and type of results that will be presented. LBA will generally not be accepted at a later date unless a shell abstract has been submitted.
For information, here are the evaluation criteria :
• On the merits of your topic's originality and interest, meaningful interpretation of results
• On the attractiveness and clarity of your presentation
Once accepted for presentation, following information is applicable:
Posters can include QR codes with further information, narration or video.
Any Questions?
If you have questions regarding abstracts or need assistance, please contact:
Dr Pierre DESCARGUES - Abstracts coordinator
E-mail: pierre.descargues@chu-lyon.fr
Prof. Pierre-Adrien BOLZE - Scientific Program coordinator
E-mail: pierre-adrien.bolze@chu-lyon.fr
Thank you for your participation.